Phosphoinositide‐dependent kinase 1–associated glycolysis is regulated by miR‐409‐3p in clear cell renal cell carcinoma

Wang, Yongjun; He, Yanfa; Bai, Hongzhong; Dang, Yi; Gao, Jiang-Yan; Lv, Pei

doi:10.1002/jcb.27152

Cited by 11 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enrichment pathways have indicated that, during ccRCC carcinogenesis, changes in metabolic levels mainly contribute to the formation of tumor cells. Several studies have revealed that RCC was closely associated with glycolysis [55][56][57][58][59][60][61][62]. In normal cells, pyruvate mainly comes from glucose under normoxia.…”

Section: Discussionmentioning

confidence: 99%

A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma

Chen

Liu

Liang

et al. 2019

Aging

View full text Add to dashboard Cite

Kidney cancer ranked in the top 10 for both men and women in the estimated numbers of new cancer cases in the United States in 2018. Targeted therapies have recently been administered to patients with clear cell renal cell carcinoma (ccRCC), but the overall survival of patients at the terminal stage of the disease has not been as good as expected. It is therefore necessary to uncover efficient biomarkers for early diagnosis, and to clarify the molecular mechanisms underlying ccRCC progression and metastasis. Increased evidence has shown that long non-coding RNAs (lncRNAs) play important roles during tumor progression. In this study, 10 candidate lncRNAs with diagnostic and prognostic values in ccRCC were identified: IGFL2-AS1, AC023043.1, AP000439.2, AC124854.1, AL355102.4, TMEM246-AS1, AL133467.3, ZNF582-AS1, LINC01510 and PSMG3-AS1. Enrichment analysis revealed metabolic and functional pathways, which may be closely associated with kidney cancer tumorigenesis. Six representative processes were summarized, namely glycolysis, amino acid metabolism, lipid synthesis, reductive carboxylation, nucleotide metabolism, transmembrane transport and signal transduction. In combination, the present results provided prognostic and diagnostic biomarkers for ccRCC and might pave the way for targeted intervention and molecular therapies in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma

Chen

Liu

Liang

et al. 2019

Aging

View full text Add to dashboard Cite

show abstract

“…Higher expression of this protein was related to a lower metastasis rate and better clinical outcomes, which indicated that this protein may be protective in ccRCC patients. PDK1-pS241 is produced by the gene PDK1 according to the TCPA database and is overexpressed in many types of cancer (Wang et al, 2019). Previous reports have suggested that PDK1 plays an important role in cancer (Wang and Sun, 2018), and it is often modified by microRNAs or used as a drug target (Zhou et al, 2017;Wang and Sun, 2018;Wang et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

“…PDK1-pS241 is produced by the gene PDK1 according to the TCPA database and is overexpressed in many types of cancer (Wang et al, 2019). Previous reports have suggested that PDK1 plays an important role in cancer (Wang and Sun, 2018), and it is often modified by microRNAs or used as a drug target (Zhou et al, 2017;Wang and Sun, 2018;Wang et al, 2019). The utility of PDK1-pS241 was similar to that of MAPK-pT202Y204, showing beneficial effects for ccRCC patients.…”

Section: Discussionmentioning

confidence: 99%

Identification of a Novel Protein-Based Signature to Improve Prognosis Prediction in Renal Clear Cell Carcinoma

Chu

Zhu

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

BackgroundClear cell renal cell carcinoma (ccRCC) is one of the most common types of malignant adult kidney cancer, and its incidence and mortality are not optimistic. It is well known that tumor-related protein markers play an important role in cancer detection, prognosis prediction, or treatment selection, such as carcinoembryonic antigen (CEA), programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4), so a comprehensive analysis was performed in this study to explore the prognostic value of protein expression in patients with ccRCC.Materials and MethodsProtein expression data were obtained from The Cancer Proteome Atlas (TCPA), and clinical information were downloaded from The Cancer Genome Atlas (TCGA). We selected 445 patients with complete information and then separated them into a training set and testing set. We performed univariate, least absolute shrinkage and selection operator (LASSO) Cox analyses to find prognosis-related proteins (PRPs) and constructed a protein signature. Then, we used stratified analysis to fully verify the prognostic significance of the prognostic-related protein signature score (PRPscore). Besides, we also explored the differences in immunotherapy response and immune cell infiltration level in high and low score groups. The consensus clustering analysis was also performed to identify potential cancer subgroups.ResultsFrom the training set, a total of 233 PRPs were selected, and a seven-protein signature was constructed, including ACC1, AR, MAPK, PDK1, PEA15, SYK, and BRAF. Based on the PRPscore, patients could be divided into two groups with significantly different overall survival rates. Univariate and multivariate Cox regression analyses proved that this signature was an independent prognostic factor for patients (P < 0.001). Moreover, the signature showed a high ability to distinguish prognostic outcomes among subgroups, and the low score group had a better prognosis (P < 0.001) and better immunotherapy response (P = 0.003) than the high score group.ConclusionWe constructed a novel protein signature with robust predictive power and high clinical value. This will help to guide the disease management and individualized treatment of ccRCC patients.

show abstract

“…Previous research has shown that RCC cells, like multiple other types of cancers cells, have aberrant HIF stabilization and are dependent on aerobic glycolysis for ATP production [ 49 ]. Indeed, PDK1 high expression in ccRCC cells boosts ECAR (extracellular acidification rate) under hypoxic conditions, improves ATP production, and diminishes the oxygen consumption rate (OCR) of tumor cells, whereas these effects can be reversed by miR-409-3p [ 50 ]. Tumor immune escape is a common topic of research and is a hallmark of cancer.…”

Section: Mirnas Act As Tumor Suppressors In Renal Cancermentioning

confidence: 99%

A Review of Recent Research on the Role of MicroRNAs in Renal Cancer

Yang

Zou

et al. 2021

Med Sci Monit

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a most common type of urologic neoplasms; it accounts for 3% of malignant tumors, with high rates of relapse and mortality. The most common types of renal cancer are clear cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), and chromophobe renal carcinoma (chRCC), which account for 90%, 6–15%, and 2–5%, respectively, of all renal malignancies. Although surgical resection, chemotherapy, and radiotherapy are the most common treatment method for those diseases, their effects remain dissatisfactory. Furthermore, recent research shows that the treatment efficacy of checkpoint inhibitors in advanced RCC patients is widely variable. Hence, patients urgently need a new molecular biomarker for early diagnosis and evaluating the prognosis of RCC. MicroRNAs (miRNAs) belong to a family of short, non-coding RNAs that are highly conserved, have long half-life evolution, and post-transcriptionally regulate gene expression; they have been predicted to play crucial roles in tumor metastasis, invasion, angiogenesis, proliferation, apoptosis, epithelial-mesenchymal transition, differentiation, metabolism, cancer occurrence, and treatment resistance. Although some previous papers demonstrated that miRNAs play vital roles in renal cancer, such as pathogenesis, diagnosis, and prognosis, the roles of miRNAs in kidney cancer are still unclear. Therefore, we reviewed studies indexed in PubMed from 2017 to 2020, and found several studies suggesting that there are more than 82 miRNAs involved in renal cancers. The present review describes the current status of miRNAs in RCC and their roles in progression, diagnosis, therapy targeting, and prognosis of RCC.

show abstract

Phosphoinositide‐dependent kinase 1–associated glycolysis is regulated by miR‐409‐3p in clear cell renal cell carcinoma

Cited by 11 publications

References 29 publications

A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma

A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma

Identification of a Novel Protein-Based Signature to Improve Prognosis Prediction in Renal Clear Cell Carcinoma

A Review of Recent Research on the Role of MicroRNAs in Renal Cancer

Contact Info

Product

Resources

About